Возможности замены одного антиагрегантного препарата на другой у пациентов, получающих двойную антиагрегантную терапию

Therapeutic potential of replacement of one antiagregant by another one in patients receiving double antiaggregant therapy Double antiaggregant therapy reduces the risk of adverse cardiovascular events. There are currently several P2Y12 platelet receptor inhibitors available, which suggests that not only optimal therapy needs to be chosen, but a patient can also be switched from one drug to another. At present, there are limited research data, as well as guidelines based largely on the experts’ opinions on replacing one drug by another. The existing options for changing double antiaggregant therapy should be taken into account in order to achieve optimal treatment outcomes for each patient.